Últimas noticias sobre Medtronic (NYSE:MDT) Bolsa

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BIDU

SOHU

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: MDT, BIDU, SOHU, OXY y FLR.

5 acciones en el foco este martes: MDT, BIDU, SOHU, OXY y FLR

FLNT

PANW

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: LOW, PANW, MDT, FLNT y ALC.

5 acciones en el foco este martes: LOW, PANW, MDT, FLNT y ALC

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

<ul>
<li>Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as&nbsp;a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to&nbsp;the U.S. Food and Drug Administration</li>
</ul>

Reported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study

<ul>
<li>One-year clinical trial data for the next-generation, investigational, Sphere-360&#x2122; single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib</li>
<li>Dual-energy (RF/PF), focal Sphere-9&#x2122; catheter demonstrates efficacy for linear ablation in persistent AFib</li>
<li>Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting</li>
</ul>

Reported Saturday, Medtronic's Affera Sphere-360 Catheter Demonstrates Safety And Performance Results For Paroxysmal AFib

Biotech

General

Medtronic Receives U.S FDA Approval For The Omniasecure Defibrillation Lead For Placement Within The Right Ventricle

Medtronic&nbsp;plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring (CGM) sensor based on Abbott's most advanced CGM platform.
The submissions included a 510(k) application for its MiniMed&#x2122; 780G pump as an alternate controller enabled (ACE) insulin pump and a separate 510(k) application for its SmartGuard&#x2122; algorithm as an interoperable automated glycemic controller (iAGC).
"We understand how meaningful these advancements are, and we're working with urgency to bring enhanced CGM options to our customers," said Que Dallara, EVP &amp; president, Medtronic Diabetes. "This collaboration with Abbott marks an important step forward in providing innovative solutions and more choice for our customers."
This milestone follows the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4412586-1&amp;h=2453851801&amp;u=https%3A%2F%2Fnews.medtronic.com%2F2024-08-07-Medtronic-announces-FDA-approval-of-Simplera-TM-CGM-and-global-partnership-with-Abbott&amp;a=announcement+last+August">announcement last August</a> that the companies will collaborate on an integrated system based on Abbott's most advanced CGM platform. Abbott will supply Medtronic with a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and smart multiple daily injections systems. These systems, including the Abbott CGM, will be sold exclusively by Medtronic.

Medtronic Announces It Has Submitted 510(K) Applications To U.S. Food And Drug Administration Seeking Clearance For An Interoperable Pump

BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension who are the focus of the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Secures FDA Breakthrough Device Designation For AVIM Therapy, Targeting 7.7M U.S. Patients With Uncontrolled Hypertension

Latest approval expands Medtronic CGM portfolio in the U.S.

Reported Saturday, Medtronic's MiniMed 780G System Gains FDA Clearance For Simplera Sync, Offering Users Greater Flexibility And Innovation

Three <a href="https://www.benzinga.com/etfs">healthcare-themed ETFs</a> were in sharp spotlight Thursday as the sector got through a wild trading day, fueled by UnitedHealth&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) earnings disappointment and steep stock decline. While insurers weighed down on broad healthcare gauges, a drugmakers rally, led by Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), limited the damage.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
ETFs In Spotlight
Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)
<ol>
<li></li>
</ol>
1-Day Return (Thursday): -0.6%
Top holdings of this fund are Eli Lilly, UnitedHealth, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>). UnitedHealth dropped 2.4%, spooking XLV early in the session. The ETF trimmed losses, however, as Eli Lilly rallied 14.3% on <a href="https://www.benzinga.com/general/biotech/25/04/44878381/eli-lilly-rallies-over-14-notches-best-day-since-june-2000-on-oral-weight-loss-drug-results-analysts-react">good weight-loss pill trial news</a>, calling out the group&#8217;s internal divergency. Barring Thursday&#8217;s turmoil, though, XLV is off just 1.5% for the year so far and commands a 17x forward-earnings multiple—below its five-year history and the large-cap S&amp;P 500&#8217;s 20x multiple, according to Barron&#8217;s.
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
<ol start="2">
<li></li>
</ol>
1-Day Performance: +4.6%
IHE surged as investors rotated into large-cap pharma stocks, bolstered by Eli Lilly's rally. The gains came despite a nearly 8% drop in Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Lilly's rival in the GLP-1 space.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
<ol start="3">
<li></li>
</ol>
1-Day Performance: +2.15%
XPH tracked gains across a broader basket of pharmaceutical names, benefiting from bullish sentiment on drugmakers following Lilly's breakthrough.
Market Context: A Sector Of Contrasts
UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">poor earnings and soft guidance</a> spooked healthcare investors, highlighting how exposed insurers are to firm-specific disappointments and policy-level risks. The 22% decline in the stock not only heavily burdened XLV—where it is the second-largest position—but pulled down peers CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) too.
However, the overall message of the day was one of subtlety and not panic. Eli Lilly&#8217;s explosion proved the influence of innovation in developing market-driving catalysts within the health-care sector. It provided the stimulus that helped neutralize weakness within managed care and indicated how investors in ETFs are able to still uncover segments of strength despite sector-wide selloffs.
At the same time, Johnson &amp; Johnson kept its steady pace going with the help of strong earnings.
Device and medical equipment manufacturers like Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), and Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) are also attracting investor attention as Wall Street is wagering on secular demand from the aging population.
Takeaway
The health care industry remains far from monolithic. Thursday&#8217;s ETF action underscored the increasing divide between pressured insurers and pharma names benefiting from innovation tailwinds. For investors in ETFs, the message is simple: thematic selectivity is key. Though political headlines and earnings fluctuations might continue to shock portions of the industry, solid fundamentals within pharma and medtech imply there&#8217;s still ample healthy opportunity to go around.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Image: Shutterstock/The Image Party

Sector ETFs

ETFs

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot

U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip <a href="https://www.benzinga.com/topic/china">export restrictions to China.</a>
The U.S. government has barred Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from selling its H20 chips to China — a move that could wipe out an estimated $5.5 billion from the company's projected quarterly revenue. Nvidia shares slid nearly 7%.
Other chipmakers also felt the heat. Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 6% as its MI308 chips fall under the new licensing requirements.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) sank 3.4%, extending the sector&#8217;s losses. Adding to the drag, Dutch chip equipment giant ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) missed quarterly revenue estimates, sending its shares down 5%.
On the macro front, March retail sales surprised to the upside, rising 1.4% month-over-month — topping forecasts of 1.3% and marking the strongest monthly <a href="https://www.benzinga.com/25/04/44837237/march-retail-sales-post-highest-surge-in-over-two-years-as-us-consumers-anticipate-tariff-jitters">gain since January 2023.</a>
Meanwhile, the U.S. dollar saw renewed selling pressure, with the dollar index dipping back below 100. Treasury yields were little changed, with the 10-year yield holding steady near 4.33%.
Gold continued its stellar run, surging 2.5% to a fresh record high of $3,320 per ounce as demand for safe-haven assets remains robust.
In commodities, oil prices rebounded sharply, with WTI crude climbing 2% to $62 a barrel. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also edged up 1.3% to around $84,500.
All eyes are now on Fed Chair Jerome Powell, who is set to speak at the Economic Club of Chicago later this afternoon.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,318.86</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,872.38</td>
<td>-0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,340.12</td>
<td>-1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,501.22</td>
<td>-1.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 11:30 a.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.9% to $532.68.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $403.09.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;tanked 1.7% to $450.31.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.5% to $185.84.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.1%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.2%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>5.39%</td>
</tr>
<tr>
<td>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>4.33%</td>
</tr>
<tr>
<td>The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)</td>
<td>4.17%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>3.92%</td>
</tr>
<tr>
<td>The Mosaic Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>)</td>
<td>3.84%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Wednesday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>)</td>
<td>-8.40%</td>
</tr>
<tr>
<td>NVIDIA Corporation </td>
<td>-6.81%</td>
</tr>
<tr>
<td>Advanced Micro Devices, Inc.</td>
<td>-5.81%</td>
</tr>
<tr>
<td>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>-4.77%</td>
</tr>
<tr>
<td>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>)</td>
<td>-4.71%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44832771/the-ball-is-in-chinas-court-trump-says-as-white-house-awaits-beijings-call-china-needs-to-make-a-deal-with-us">&#8216;The Ball Is In China&#8217;s Court&#8217;: Trump Says As White House Awaits Beijing&#8217;s Call — &#8216;China Needs To Make A Deal With Us&#8217;</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

JBHT

KLAC

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Select Sector SPDR-Consumer Discretionary

Nvidia Drags Wall Street Down, Gold Defies Gravity Ahead Of Powell Remarks: What's Driving Markets Wednesday?

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and lowers the price target from $93 to $90.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $90

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 4.76% since its last report. The company recently reported that it has 12.83 million shares sold short, which is 1.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744034457_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

Reported Sunday, Medtronic Evolut TAVR Demonstrates Sustained Valve Performance And Lower Cardiovascular Mortality Trend At 5 Years

On Sunday, Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Cargill, and other major firms.
What Happened: "China will continue to improve the business environment and welcome more investment by multinational companies in China, sharing opportunities for development," he told the leaders, describing the country's economy as "highly resilient" and "full of vitality."
Executives from medical device maker Medtronic PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and investment management firm Conning were also in attendance, reported Reuters, citing a statement from China's Ministry of Commerce.
However, the statement did not specify where the meeting took place.
Many of the executives are in Beijing to attend the China Development Forum, where further high-level meetings, including a possible session with President Xi Jinping, are expected later this week, the report noted, citing unnamed sources.
See Also:&nbsp;<a href="https://www.benzinga.com/25/03/44272657/alibaba-chairperson-says-everyone-is-concerned-about-tariffs-as-he-expects-levies-on-chinese-evs" target="_blank" rel="noreferrer noopener">Alibaba's Joseph Tsai Says ‘Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs</a>
Why It's Important: Beijing has ramped up efforts to attract foreign capital amid a slowing economy and fresh <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">U.S. tariff headwinds</a> under President Donald Trump.
While American companies made up the largest group at this year's forum, sources say fewer U.S. CEOs attended compared to last year—signaling ongoing caution in cross-border corporate relations, the report noted.
Previously, the Chinese President expressed concerns about the possibility of China facing isolation similar to the Soviet Union during the Cold War. The ongoing trade war has heightened <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">fears of economic isolation</a>.
 Despite these challenges, <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production">China remains a leader</a> in technological advancements, particularly in artificial intelligence and robotics, according to investor Ray Dalio.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon's ‘Beast Games'—Now He's Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Media

AAPL

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

High-rolling investors have positioned themselves bullish on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MDT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Medtronic. This is not a typical pattern.
The sentiment among these major traders is split, with 62% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $38,125, and 7 calls, totaling $895,860.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $82.5 to $92.5 for Medtronic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $92.5 in the last 30 days. 
<h3>Medtronic 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742576490_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.35</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$85.00</td>
<td>$287.2K</td>
<td>4.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$90.00</td>
<td>$220.6K</td>
<td>1.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$87.50</td>
<td>$205.2K</td>
<td>419</td>
<td>390</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$87.50</td>
<td>$54.8K</td>
<td>588</td>
<td>126</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.94</td>
<td>$1.8</td>
<td>$1.84</td>
<td>$90.00</td>
<td>$48.1K</td>
<td>916</td>
<td>409</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Following our analysis of the options activities associated with Medtronic, we pivot to a closer look at the company's own performance.
<h3>Current Position of Medtronic</h3>
<ul>
<li>With a trading volume of 3,457,096, the price of MDT is down by -0.69%, reaching $90.59.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Expert Opinions on Medtronic</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $107.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Citigroup upgrades its rating to Buy with a revised price target of $107. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Medtronic's Recent Unusual Options Activity

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation" title="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation">https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation</a>

FDA Says Medtronic Removes Unused 027 Compatible Pipeline Vantage Embolization Device With Shield Technology; Medtronic Updates Use Instructions For 021 Compatible Pipeline Vantage Embolization Devices; Medtronic Updates Instructions For Using Pipeline Vantage 021 Device Models Due To Risk Of Incomplete Wall Apposition & Braid Deformation

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial&nbsp;to primarily enroll women using the two most widely used global TAVR devices

Reported Sunday, Medtronic Evolut TAVR Demonstrates Superior Durability And Valve Function In Small Annulus Patients, SMART Trial Shows

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson analyst Rudy Kessinger upgraded the rating for Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Neutral to Buy and raised the price target from $90 to $125. Okta shares closed at $87.16 on Monday. <a href="https://www.benzinga.com/quote/okta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Aman Rakkar upgraded the rating for HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) from Equal-Weight to Overweight. HSBC shares closed at $60.33 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Joanne Wuensch upgraded Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raised the price target from $92 to $107. Medtronic shares closed at $94.30 on Monday. <a href="https://www.benzinga.com/quote/mdt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Julien Dumoulin-Smith upgraded The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) from Underperform to Neutral and raised the price target from $11 to $13. AES shares closed at $11.19 on Monday. <a href="https://www.benzinga.com/quote/aes/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded the rating for Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) from Sector Weight to Overweight and maintained the price target of $260. Nordson shares closed at $207.10 on Monday. <a href="https://www.benzinga.com/quote/ndsn/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

HSBC

NDSN

OKTA

This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Throughout the last three months, 5 analysts have evaluated Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $97.4, accompanied by a high estimate of $107.00 and a low estimate of $89.00. Witnessing a positive shift, the current average has risen by 4.73% from the previous average price target of $93.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741093276_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Medtronic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Delving into Medtronic's Background</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Unraveling the Financial Story of Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Medtronic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.51% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.64%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Medtronic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Medtronic's Future

Citigroup analyst Joanne Wuensch upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raises the price target from $92 to $107.

Citigroup Upgrades Medtronic to Buy, Raises Price Target to $107

On Monday, the FDA approved Medtronic plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43911731/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-p" rel="noreferrer noopener">with Parkinson&#8217;s disease</a>.
Deep brain stimulation uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for Parkinson&#8217;s.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43782957/medtronic-q3-earnings-cardiovascular-and-neuroscience-drive-growth-surgical-revenue-dips-reaffirms-annual-forecast" rel="noreferrer noopener">Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast</a>
This feature personalizes therapy based on a patient&#8217;s brain activity in real-time – both in clinical settings and daily life.
It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.
BrainSense Adaptive DBS is available to Medtronic DBS patients with Parkinson&#8217;s who have been implanted with a Percept neurostimulator and future Medtronic DBS patients.
The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson&#8217;s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice.
The FDA approval also includes the Medtronic BrainSense Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. Using EI, clinicians can conduct an accurate and precise initial programming, 85% faster than traditional electrode selection.
BrainSense aDBS and EI are also&nbsp;available&nbsp;in&nbsp;Europe. Patient programs in&nbsp;the United States&nbsp;will begin at select healthcare systems over the coming weeks, with availability nationwide in the coming months.
Price Action: MDT stock is up 0.85% at $90.70 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech" target="_blank" rel="noreferrer noopener">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a></li>
</ul>
Photo via Shutterstock

Health Care

FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients

New closed-loop system self-adjusts DBS therapy to individual brain activity&nbsp;in real time; the largest commercial launch of brain-computer interface technology ever&nbsp;
GALWAY, Ireland, Feb. 24, 2025 /PRNewswire/ --&nbsp;For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI).
There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Now Medtronic has enhanced its Percept&#x2122; DBS neurostimulators with exclusive BrainSense&#x2122; Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – both in clinical settings and in daily life2. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.

Medtronic Earns U.S. FDA Approval For The World's First Adaptive Deep Brain Stimulation System For People With Parkinson's

Press Releases

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

New Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

AVAI

GELS

ILMN

MDAI

PNPNF

PRSO

TIVC

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Truist Securities

Citigroup

RBC Capital

Baird

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Medtronic

Noticias

Últimas noticias sobre Medtronic (NYSE:MDT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL